Asthma inhaler / Richard - stock.adobe.comThe single-center retrospective cohort study is published in Annals of Medicine.1Key Takeaways Biologic therapies are a promising treatment option for patients with severe asthma, with 35.5% of patients achieving complete response after 55 months of treatment. Airflow obstruction was identified as the main hurdle to achieving complete response with biologic therapies. The rates of complete response identified were 30.2% in patients treated with omalizumab, 30.4% in patients with benralizumab, and 52.6% in patients with mepolizumab. Additionally, long-term complete response was associated with better lung function in patients treated with mepolizumab and omalizumab, whereas long-term complete response was associated with fewer previous exacerbations in patients treated with benralizumab. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.

Source: New York Times February 28, 2024 21:52 UTC